Treatments for MPS I, either hematopoietic stem cell transplant (HSCT) or intravenous enzyme replacement therapy (ERT) with recombinant human IDUA (rhIDUA), have reduced disease burden and extended life expectancy of MPS I patients into adulthood [6, 7]. The gene discussed is IDUA; the disease is Scheie syndrome.